Question

A newly discovered compound is being compared in clinical trials to the current standard of care treatment. The standard of care treatment for this disease is associated with the therapeutic effect of the drug but also with some moderate adverse effects that are seen ina large number of patients who receive this treatment. The newly discovered compound produces the therapeutic effect of the drug but does not produce unwanted side effects associated with the standard of care treatment. Which of the following could explain this? The newly discovered compound is a biased antagonist for the pathway associated with the therapeutic effect of the drug The newly discovered compound has a higher selectivity for the molecular target associated with the therapeutic effect of the drug The newly discovered compound has a higher affinity for the molecular target associated with the unwanted side effects The newly discovered compound is a biased agonist for the pathway associated with the unwanted side effects

Answer 1

discovered Compound has a higher option b : @ The newly Selectivity for the molecular target assosiated with the therapeutic effect of the drug. * The newly discovered compound produces the therapeutic effect of doug but does not produce unwanted side effects, which means the drug is highly selective, because it Shows action on molecular target and does not produce Unwanted sideeffects. * The drug does not show any adverse effets means, it has selectivity. Selectivity is the ability to reject falte positives.